Keytruda TNBC Approval Now More Likely, But Data Is Bad News For pCR Surrogate Endpoint

 
• By Alaric DeArment

Merck unveiled event-free survival results for Keytruda in triple-negative breast cancer following failure earlier this year to gain approval on a surrogate endpoint.

Keytruda's TNBC claim appears on a solid launch trajectory, but the pCR surrogate endpoint may not make the rest of the trip to approval. • Source: Alamy

More from Product Reviews

More from Pink Sheet